Lipid Disorders
From the Journals
‘Weekend warrior’ exercise pattern sufficient to cut mortality
The “weekend warrior” exercise pattern – having one or two rather than five to seven leisure-time activity sessions per week – may be sufficient...
Conference Coverage
VIDEO: New antisense inhibitor nets impressive reductions in lipids
NEW ORLEANS – A new antisense inhibitor to angiopoietinlike protein 3 (ANGPTL3) reduces lipids in healthy adults with elevated triglyceride levels...
From the Journals
Statins protect against Alzheimer’s in most patients
Statins taken to reduce cholesterol also protect most patients against Alzheimer’s disease, but the decrease in risk varies across different...
News from the FDA/CDC
Empagliflozin first antidiabetes drug to gain cardioprotective indication
Empagliflozin is the first antidiabetes medication to be approved for reducing the risk of cardiovascular death in patients with type 2 diabetes...
Conference Coverage
VIDEO: MILANO-PILOT marks end of the road for HDL mimetic
Among 120 patients with recent acute coronary syndrome, a mimetic known as MDCO-216 was no better than placebo at reducing coronary plaque...
Conference Coverage
GLAGOV finds evolocumab plus statin drives unprecedented plaque regression
NEW ORLEANS – Adding evolocumab to statin therapy resulted in unprecedented coronary atheromatous plaque regression in the GLAGOV study.
Conference Coverage
VIDEO: Novel agent inclisiran dramatically lowers LDL
NEW ORLEANS – A more convenient and likely less expensive alternative to the PCSK9-inhibiting monoclonal antibodies for massive LDL-lowering is...
Feature
Diabetes drugs with cardiovascular benefits broaden cardiology’s turf
Some cardiologists are acting like diabetologists now that they have antidiabetic drugs that can reduce CVD events in patients with type 2...
Conference Coverage
An enlightened approach to weight loss using liraglutide
It’s possible to identify by week 16 of liraglutide for weight loss which patients will go on to show clinically meaningful weight reduction at 56...
Conference Coverage
14% of ASCVD patients need a PCSK9 inhibitor to reach LDL goal
ROME – Fourteen percent of patients with atherosclerotic cardiovascular disease won’t reach the goal of an LDL cholesterol level below 70 mg/dL...
Conference Coverage
Mediterranean diet for secondary prevention cuts all-cause mortality
ROME – Adherence to the Mediterranean diet by patients with known cardiovascular disease provides powerful protection against mortality beyond...